Glaukos Debt to Equity Ratio 2014-2022 | GKOS

Current and historical debt to equity ratio values for Glaukos (GKOS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Glaukos debt/equity for the three months ending September 30, 2022 was 0.64.
Glaukos Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-09-30 $0.46B $0.55B 0.84
2022-06-30 $0.47B $0.56B 0.83
2022-03-31 $0.46B $0.60B 0.76
2021-12-31 $0.46B $0.59B 0.79
2021-09-30 $0.46B $0.60B 0.77
2021-06-30 $0.46B $0.58B 0.79
2021-03-31 $0.43B $0.59B 0.73
2020-12-31 $0.34B $0.67B 0.51
2020-09-30 $0.33B $0.66B 0.50
2020-06-30 $0.33B $0.66B 0.50
2020-03-31 $0.14B $0.64B 0.22
2019-12-31 $0.15B $0.67B 0.22
2019-09-30 $0.12B $0.19B 0.62
2019-06-30 $0.11B $0.19B 0.61
2019-03-31 $0.04B $0.19B 0.23
2018-12-31 $0.03B $0.17B 0.19
2018-09-30 $0.03B $0.16B 0.17
2018-06-30 $0.02B $0.15B 0.15
2018-03-31 $0.02B $0.14B 0.14
2017-12-31 $0.03B $0.14B 0.20
2017-09-30 $0.02B $0.13B 0.16
2017-06-30 $0.02B $0.13B 0.16
2017-03-31 $0.02B $0.12B 0.12
2016-12-31 $0.02B $0.12B 0.15
2016-09-30 $0.02B $0.11B 0.17
2016-06-30 $0.02B $0.11B 0.18
2016-03-31 $0.02B $0.10B 0.19
2015-12-31 $0.02B $0.10B 0.23
2015-09-30 $0.02B $0.10B 0.24
2015-06-30 $0.03B $0.10B 0.35
2015-03-31 $0.03B $-0.00B -7.49
2014-12-31 $0.03B $-0.00B -8.38
2014-09-30 $0.00B $0.00B 0.00
2014-06-30 $0.00B $0.00B 0.00
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.02B $0.01B 3.31
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $2.281B $0.294B
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $220.806B 23.09
Edwards Lifesciences (EW) United States $47.328B 32.57
Alcon (ALC) Switzerland $34.365B 29.59
STERIS (STE) Ireland $19.157B 23.84
Teleflex (TFX) United States $11.379B 18.46
Fresenius Medical Care AG KGaA (FMS) Germany $9.600B 9.64
Penumbra (PEN) United States $8.008B 1916.82
Globus Medical (GMED) United States $7.483B 38.05
Integer Holdings (ITGR) United States $2.426B 19.47
Nevro (NVRO) United States $1.601B 0.00
Paragon 28 (FNA) United States $1.511B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.261B 17.96
Artivion (AORT) United States $0.546B 0.00